CAJ | 학술논문

目的观察非那雄胺联合M受体拮抗剂(酒石酸托特罗定缓释片)治疗良性前列腺增生(BPH)伴膀胱过度活动症(OAB)患者的临床疗效. 方法选择BPH伴OAB患者40例,口服非那雄胺(5 mg/d)和酒石酸托特罗定缓释片(4 mg/d)6个月,在治疗前和治疗6个月后分别评价国际前列腺症状评分(IPSS)、膀胱过度活动症评分(OABSS)、尿急次数、最大尿流率、残余尿量、前列腺体积等指标. 结果治疗后IPSS评分(11.8±1.4)分、OABSS评分(4.6±2.6)分、尿急次数(1.2±1.9)次/周、最大尿流率(14.5±2.7)ml/s、残余尿量(25.2±2.6)ml、前列腺体积(46.2±2.2)ml,较治疗前(19.2±2.1)分、(9.3±1.8)分、(4.7±1.0)次/周、(10.2±2.2)ml/s、(34.6±3.2)ml、(57.6±1.3)ml差异有统计学意义(t=3.21、2.54、2.39、4.73、6.56、5.18,均P＜0.05).40例患者均未出现尿潴留及明显不良反应. 结论非那雄胺联合M受体拮抗剂治疗BPH伴OAB患者疗效显著,安全良好.
목적 관찰비나웅알연합M수체길항제(주석산탁특라정완석편)치료량성전렬선증생(BPH)반방광과도활동증(OAB)환자적림상료효. 방법 선택BPH반OAB환자40례,구복비나웅알(5 mg/d)화주석산탁특라정완석편(4 mg/d)6개월,재치료전화치료6개월후분별평개국제전렬선증상평분(IPSS)、방광과도활동증평분(OABSS)、뇨급차수、최대뇨류솔、잔여뇨량、전렬선체적등지표. 결과 치료후IPSS평분(11.8±1.4)분、OABSS평분(4.6±2.6)분、뇨급차수(1.2±1.9)차/주、최대뇨류솔(14.5±2.7)ml/s、잔여뇨량(25.2±2.6)ml、전렬선체적(46.2±2.2)ml,교치료전(19.2±2.1)분、(9.3±1.8)분、(4.7±1.0)차/주、(10.2±2.2)ml/s、(34.6±3.2)ml、(57.6±1.3)ml차이유통계학의의(t=3.21、2.54、2.39、4.73、6.56、5.18,균P＜0.05).40례환자균미출현뇨저류급명현불량반응. 결론 비나웅알연합M수체길항제치료BPH반OAB환자료효현저,안전량호.
Objective To observe the efficacy of finasteride and M-receptor antagonist (tolterodine tartrate release tablet) in patients with benign prostatic hyperplasia (BPH) with overactive bladder (OAB).Methods 40 patients with BPH and OAB were treated with finasteride (5 mg,Qd) and tolterodine tartrate release tablet (4 mg,Qd) for 6 months.The clinical effects were evaluated by the International Prostate Symptom Score (IPSS),Overactive Bladder Symptom Score (OABSS),urgency rating scale,maximum flow rate,voiding volume,prostate volume before and after treatment.Results Compared with before treatment,the IPSS,OABSS,urgency rating scale,maximum flow rate,voiding volume,prostate volume were improved [(11.8±1.4) vs.(19.2±2.1),(4.6±2.6) vs.(9.3±1.8),(1.2±1.9) times/week vs.(4.7±1.0) times/week,(14.5±2.7) ml/s vs.(10.2±2.2) ml/s,(25.2±2.6) ml vs.(34.6±3.2) m1,(46.2±2.2) ml vs.(57.6±1.3) ml,all P＜0.05] after treatment.No urinary retention and other adverse reactions were found.Conclusions Finasteride combined with M-receptor antagonist (tolterodine tartrate release tablet) is an effective and safe therapeutic method for patients with BPH and OAB.